JPAD-Journal of Prevention of Alzheimers Disease

Article	Citations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	607
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	356
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	120
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	95
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	87
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	83
Herpes zoster and dementia : more evidences for a causal link	73
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease	63
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	63
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	56
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease	51
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.	45
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	41
Gene and genetic therapies in Alzheimer’s disease and other dementias	39
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia	33
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	32
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	31
Informal care for people with dementia in Europe	28
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care	28
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	28
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system	27
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration	26
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities	26
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease	25
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review	23

Aducanumab: Appropriate Use Recommendations	22
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	21
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese	21
Introduction to the Special Issue on the A4 Study	21
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias	21
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population	20
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test	19
Donanemab: Appropriate use recommendations	19
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease	18
Erratum to: Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome	18
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6	18
Erratum to: Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease	18
The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer's Disease or Amnesic Mild Cognitive Impairment	17
Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis	16
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions	16
Cardiovascular-kidney-metabolic syndrome and incidence of dementia among older adults	16
Differential effects of soluble and plaque amyloid on late-life depression: The moderating role of tau pathology	15
Longitudinal Impacts of Precision Greenness on Alzheimer's Disease	15
The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort	15
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?	15
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum	15
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment	15
Treatments for Alzheimer’s and the declaration of Helsinki	14
New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study	14
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature	14
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis	14
Global Burden of Dementia Death from 1990 to 2019, with Projections to 2050: An Analysis of 2019 Global Burden of Disease Study	14
Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform	13
Preclinical detection of Alzheimer’s disease pathology using conceptual discrimination abilities	13
Trajectories of muscle strength and physical performance preceding dementia in older US and European populations	13
Blood pressure and Alzheimer’s disease biomarkers in cognitively unimpaired adults: a multicenter study	13
Adherence to an anti-inflammatory diet is associated with lower Alzheimer’s disease mortality: A modifiable risk factor in a national cohort	13
16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters	13
Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review	12
The Causal Relationship between Genetically Predicted Biological Aging, Alzheimer's Disease and Cognitive Function: A Mendelian Randomisation Study	12
Where Do We Go from Here?	12
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy	12
Reply to Letter to the Editor: “Early-Onset Type 2 Diabetes and Risk of Dementia”	12
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4	12
Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis	12
Plasma amyloid-β precursor protein 669–711/amyloid-β1–42 ratio is associated with cognition in Alzheimer's disease	11
Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study	11
Identifying the optimal combinations of modifiable dementia risk factors to target in multidomain intervention – Three-year longitudinal findings from the Canadian longitudinal study on aging	11
Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults	11
Basal forebrain global functional connectivity is preserved in asymptomatic presenilin-1 E280A mutation carriers: Results from the Colombia cohort	11
Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study	11
Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies	11
Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabece	11
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort	11
Erratum to: Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults	11

A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice	11
Corrigendum to “17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Symposia, Oral Communications” [J Prev Alzheimers Dis 2025;12(1S):100043].	11
Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets	10
Cardiovascular health, genetic predisposition, and dementia risk among atherosclerotic cardiovascular disease patients	10
Brain photobiomodulation: a potential treatment in Alzheimer’s and Parkinson’s diseases	10
Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance	10
Modulatory Effect of Blood LDL Cholesterol on the Association between Cerebral Aβ and Tau Deposition in Older Adults	10
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review	10
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis	10
Disclosure of Alzheimer’s disease blood-based biomarker results in a primary care setting: Opportunities and challenges	10
17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024	10
Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EM	10
Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the CTAD Meeting in San Francisco, November 29–December 2 2022	10
Serum BDNF and progression to MCI in cognitively normal older adults A prospective cohort study	10
The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis	10
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry	9
Long-term cumulative physical activity associated with less cognitive decline: Evidence from a 16-year cohort study	9
Structural equation modeling confirms interaction of Alzheimer’s disease and vascular disease in hippocampal injury	9
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report	9
Association of Preeclampsia with Incident Dementia and Alzheimer's Disease among Women in the Framingham Offspring Study	9
Feasibility of computerized motor, cognitive and speech tests in the home: Analysis of TAS Test in 2,300 older adults	9
Interest in and Experience with Genetic Testing for Late-Onset Medical Conditions: Results from the National Poll on Healthy Aging	9
Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)	9
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials	9
Relationships of Hypnotics with Incident Dementia and Alzheimer's Disease: A Longitudinal Study and Meta-Analysis	9
The ‘Aducanumab Story': Will the Last Chapter Spell the End of the ‘Amyloid Hypothesis' or Mark a New Beginning?	9
Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study	9
Early detection of Alzheimer’s disease using small RNAs. Results from the EPAD cohort	9
The Clinical Trials Alzheimer's Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!	9
The differential effect of strength, cognitive and aerobic training combinations on cognitive performance and functional abilities in elderly with cognitive decline: The Fit4Alz project	9
The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland	8
Symposia — Oral Communications — Late Breaking News	8
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)	8
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease	8
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer's Disease Progression	8
Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective	8
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study	8
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	8
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform	8
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force	8
Editorial Board	8
The Association between Peanut and Peanut Butter Consumption and Cognitive Function among Community-Dwelling Older Adults	8
First Experiences with Amyloid-Related Imaging Abnormalities — Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management	8
Association of Multi-Domain Factors with Cognition in the UK Biobank Study	8
Fingolimod ameliorates amyloid deposition and neurodegeneration in APP/PS1 mouse model of Alzheimer's disease	8
Posters	8
Universal Prevention of Dementia in Italy: A Document Analysis of the 21 Italian Regional Prevention Plans	8
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration	8
Prevention of Alzheimer's Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference	7
Embryo Selection for a Carrier of an Early-Onset Alzheimer's Disease-Associated Mutation in the PSEN1 Gene	7
Reducing the Effects of Ageing on Cognition with Therapeutic Intervention of an Oral Multi-Nutrient: The REACTION Pilot Trial Study Design	7
The role of serum vitamins in mediating the effect of neurodegenerative diseases on subcortical brain volume	7
Decreased Gray—White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea	7
Stress internalization is a top risk for age-associated cognitive decline among older Chinese in the U.S	7
Aducanumab: Appropriate Use Recommendations	7
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease	7
Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials	7
How Will Aducanumab Approval Impact AD Research?	7
The Dawn of a New Era of Alzheimer's Research and Drug Development	7
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults	7
Prevalence and co-occurrence of dementia risk factors in Denmark: A nationwide study	7
Response to “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	7
Polyunsaturated fatty acids, APOE genotypes, and dementia incidence and mortality among hypertensive adults	7
Flavonoid-Rich Fruit Intake in Midlife and Late-Life and Associations with Risk of Dementia: The Framingham Heart Study	7
Peripheral Blood BRCA1 Methylation Positively Correlates with Major Alzheimer's Disease Risk Factors	7
The Future is Now: Advancing Blood-Based Markers	7
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline in Preclinical Alzheimer's Disease: The A4 Study	7
«Compounded Interest» in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use	7
Early-Onset Type 2 Diabetes and Risk of Dementia	6
At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer's Disease and Related Research	6
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients	6
Latent cognitive profiles and their associations with instrumental activities of daily living among older adults without dementia: A United States national cross-sectional study	6
Assessing the causal role of lipid metabolites in Alzheimer's disease: A mendelian randomization study	6
A Fay-Herriot Model for Estimating Subjective Cognitive Decline among Military Veterans	6
Microglial activation states and their implications for Alzheimer's Disease	6
A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease	6
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults	6
Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paper	6
Associations and Potential Multiple Mechanisms between Subjective Hearing Loss and Cognitive Impairment	6
Higher Cognitive Reserve Is Beneficial for Cognitive Performance Via Various Locus Coeruleus Functional Pathways in the Pre-Dementia Stage of Alzheimer's Disease	6

Comparative efficacy of cognitive training modalities in cognitive impairment: A systematic review and network meta-analysis	6
Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners	6
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies	6
High Intake of Dietary Cholesterol Decreases the Risk of All-Cause Dementia and AD Dementia: A Results from Framingham Offspring Cohort	6
Unveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals	6
Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease	6
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease	6
Motor abilities and cognitive performance in Latinos with autosomal dominant Alzheimer's disease	6
Visual Event-Related Potentials under External Emotional Stimuli as Early Signs for Mild Cognitive Impairment	6
Preventing dementia in Italy: Estimations of modifiable risk factors and public health implications	6
Reply to: Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	6
Comment on “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	6
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylat	6
Temporal associations of neuropsychiatric symptoms, demographics and amyloid with subsequent tau burden in older adults	6
Effects of Vitamin D3 Combined with Folic Acid on Domain and Specific Cognitive Function among Patients with Mild Cognitive Impairment: A Randomized Clinical Trial	5
Appropriate Use Recommendations for Lecanemab	5
China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress	5
“Time Saved” Calculations to Improve Decision-Making in Progressive Disease Studies	5
Brain lymphatic drainage pathways, deep cervical lymphatic surgery, and current insights: A systematic review	5
Unsupervised Performance of the CogState Brief Battery in the Brain Health Registry: Implications for Detecting Cognitive Decline	5
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease P	5
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial	5
Association between Resting Heart Rate and Machine Learning-Based Brain Age in Middle- and Older-Age	5
Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography	5
Expectancy Does Not Predict 18-month Treatment Outcomes with Cognitive Training in Mild Cognitive Impairment	5
Medical risk factors, ApoE haplotype, and Alzheimer’s disease: a large-scale analysis	5
Association of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate with cerebral small vessel disease: A large prospective cohort study	5
Corrigendum to Enhancing dementia prediction: A 19-year validation of the CAIDE risk score with insulin resistance and APOE ε4 integration in a population-based cohort	5
Gender-Specific Design and Effectiveness of Non-Pharmacological Interventions against Cognitive Decline — Systematic Review and Meta-Analysis of Randomized Controlled Trials	5
Who Benefited the Most? Effectiveness of a Lifestyle Intervention Against Cognitive Decline in Older Women and Men – Secondary Analysis of the AgeWell.de-trial	5
Development and Concurrent Validity of the Short-Form CogDrisk Dementia Risk Assessment Tool	5
Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review	5
Brain health PRO/santé cerveau PRO: The development of a web-based program for dementia literacy and risk factor reduction	5
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing	5
Mendelian Randomization Analysis Reveals Causal Factors behind Alzheimer's Disease Risk: Evidence, Opportunities, and Challenges	5
A novel early imaging biomarker for glymphatic function: Cerebral cortical arterial pulsatility index from 2-Minute phase-contrast MRI	5
A Hierarchical Bayesian Latent Class Model for the Diagnostic Performance of Mini-Mental State Examination and Montreal Cognitive Assessment in Screening Mild Cognitive Impairment Due to Alzheimer's D	5
Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis	5
Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer's Disease	5
Genetic predisposition to high circulating levels of interleukin 6 and risk for Alzheimer's disease. Discovery and replication	5
Eligibility for donanemab trial in a population-based study of cognitive aging	5
Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia	5
Anti-Hypertensive Drugs Moderate the Relationship of Blood Pressure with Alzheimer's Pathologies and Neurodegenerative Markers in Non-Demented Hypertensive Older Adults	5
Association between Family Household Income and Cognitive Resilience among Older US Adults: A Cross-Sectional Study	5
APOE ε4-related differences in brain structure, function, and connectivity at midlife: A scoping review	5
Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies	5
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States	5
Associations of ischemic heart disease with brain glymphatic MRI indices and risk of Alzheimer's disease	5
Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease	5
Corrigendum to “Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study” [The Journal of Prevention of Alzheimer's Disease 2024;11(3):567	5
Multimorbidity and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies	5
Hypnotics and Incident Dementia: A Risk Assessment	5
Cytomegalovirus Infection and Alzheimer's Disease: A Meta-Analysis	4
Mendelian Randomization Analysis to Assess Whether Magnetic Resonance Imaging Signs of Cerebral Small Vessel Disease Can Cause Cognitive Decline and Dementia	4
Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial	4
Burden of Illness in People with Alzheimer's Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality	4
The Role of Thyroid Dysfunction in Alzheimer's Disease: A Systematic Review and Meta-Analysis	4
Behaviour change techniques used in interventions targeting dementia risk factors amongst older adults in rural and remote areas: A systematic review and meta-analysis	4
Physical and mental demands of work associated with dementia risk in later life	4
Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults	4
Advancing the science of recruitment for Alzheimer’s clinical trials: Challenges and opportunities	4
Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report	4
Tau Pathologies Mediate the Associations of Vascular Risk Burden with Cognitive Impairments in Non-demented Elders: The CABLE Study	4
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease	4
Prediction of Alzheimer's Disease Based on 3D Genome Selected circRNA	4
Editorial Board	4
Content	4
A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease	4
Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease	4
Can non-pharmacological interventions change levels of neurofilament light in older adults at risk of dementia? A secondary analysis of the SCD-Well randomized clinical trial	4
Microstructural white matter injury contributes to cognitive decline: Besides amyloid and tau	4
Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults	4
Associations between Participant Characteristics and Participant Feedback about an Unsupervised Online Cognitive Assessment in a Research Registry	4
Cholinergic basal forebrain atrophy accelerates cognitive decline via cortical thinning: The moderating role of amyloid-β pathology in preclinical Alzheimer’s disease	4
Plasma p-tau217 predicting brain-wide tau accumulation in preclinical AD	4
What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer's Disease Can Be Used in Clinical Practice?	4
Alzheimer's Disease Prevention Health Coaching	4
What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?	4
Meta Analysis of the Correlation between Periodontal Health and Cognitive Impairment in the Older Population	4
Plasma neurofilament light mediates the effects of Apolipoprotein E on brain atrophy and cognitive decline in the comorbid Alzheimer's disease and cerebral small vessel disease	4
Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	4
Effectiveness of a Meta-Cognitive Group Intervention for Older Adults with Subjective Cognitive Decline or Mild Cognitive Impairment: The ASPIRE Randomized Controlled Trial	4
15th Conference Clinical Trials Alzheimer's Disease, November 29- December 2, 2022, San Francisco, CA, USA: Symposia - Oral Communications - Late Breaking Abstracts (Clinical Trial Alzheimer's Disease	4
Heightened Prevalence of Common Hospital-Treated Infections Preceding Dementia Diagnosis with Accelerated Dementia Onset after Influenza	4
Dietary Cholesterol and Dementia Risk	4
The Effects of Dual-Task Training on Cognitive and Physical Functions in Older Adults with Cognitive Impairment; A Systematic Review and Meta-Analysis	4
Periodontal Disease and Alzheimer's: Insights from a Systematic Literature Network Analysis	4
Association of dietary fatty acids with longitudinal change in plasma-based biomarkers of Alzheimer's disease	4
Leveraging Diverse Regulated Cell Death Patterns to Identify Diagnosis Biomarkers for Alzheimer's Disease	4
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report	4
Fructose Consumption is Associated with a Higher Risk of Dementia and Alzheimer's Disease: A Prospective Cohort Study	4
Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study	4
Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo	4
The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants	4
MemScreen: A smartphone application for detection of mild cognitive impairment: A validation study	4